GlassScriptPhysician profile
Leonard Koliani
NPI 1619995677
$52,137.03
in general payments reported to CMS, 2019-2025
77 companies · $6,372 in 2025
The $6,372 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $3,910 · 2021: $5,039 · 2022: $5,597 · 2023: $5,603 · 2024: $5,590 · 2025: $6,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,313.15 |
| Education | $252.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $17,641.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $6,516.05 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $3,021.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $2,635.53 | 2021-2025 | |
| Abbvie INC. | $2,620.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,466.41 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $1,595.47 | 2019-2025 | Repatha, Evenity, Repatha |
| Amarin Pharma, INC. | $1,381.09 | 2019-2023 | |
| Pfizer INC. | $1,373.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,338.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,133.82 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $1,128.97 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Allergan, INC. | $972.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $533.35 | 2019-2025 | Gardasil 9, Verquvo, Capvaxive |
| Abbott Laboratories | $462.29 | 2019-2025 | Freestyle Libre 3 |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Koliani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.